FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical trial NCT06402331 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06402331
- Sponsor
- Fusion Pharmaceuticals Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-05
- Primary completion
- 2026-12-23
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.